Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?

You've probably heard both names by now. Ozempic. Mounjaro. Wegovy. Zepbound. The ads are everywhere, the Reddit threads are endless, and your doctor either put you on one without much explanation or told you to "just lose weight" and moved on.

The semaglutide vs tirzepatide question finally has a real answer, not just indirect comparisons from separate trials. The first head-to-head randomized trial is published, and the results are worth knowing.

This article covers what each drug actually does, what the trial data shows about weight loss and side effects, how much they cost, and how a physician actually decides between them based on your labs and history.

How Each Drug Works (Without the Jargon)

Your gut releases hormones after you eat that signal your brain to stop eating and your pancreas to release insulin. Two of the most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones also slow digestion, reduce appetite, and affect how your body stores fat.

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) activates only the GLP-1 receptor. It's a single-pathway drug, and it works well. The STEP 1 trial showed an average of 14.9% body weight reduction over 68 weeks. Roughly 30 pounds if you start at 200 pounds.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) activates both GLP-1 and GIP receptors at the same time. That dual activation appears to do something semaglutide doesn't: it enhances the brain's response to GLP-1 signaling rather than just adding another dose of GLP-1 alone. The SURMOUNT-1 trial showed up to 22.5% body weight reduction with the highest dose over 72 weeks. That's 45 pounds at 200 pounds.

Whether that dual mechanism is why tirzepatide outperforms semaglutide is still debated. But the gap in outcomes is consistent across multiple studies.

The SURMOUNT-5 Trial: First Head-to-Head Results

For years, physicians could only compare these two drugs indirectly. Different trial designs, different populations, different endpoints. That changed when SURMOUNT-5 published its results in early 2025 in the New England Journal of Medicine.

SURMOUNT-5 was the first randomized controlled trial to put tirzepatide and semaglutide head-to-head in people with obesity but without type 2 diabetes. The comparison: tirzepatide (10 or 15 mg) versus semaglutide (1.7 or 2.4 mg Wegovy dosing), both weekly subcutaneous injections.

Tirzepatide produced about 47% more weight loss than semaglutide in this trial. Participants on tirzepatide lost a mean of approximately 20.2% of body weight versus 13.7% with semaglutide at 72 weeks (Mamas et al., 2025). At a starting weight of 250 pounds, that's roughly 50 pounds vs 34 pounds.

A post-hoc cardiovascular analysis from SURMOUNT-5 found that tirzepatide was associated with a 2.4% absolute reduction in predicted 10-year cardiovascular risk, compared to 1.4% for semaglutide (Mamas et al., 2025).

The SURPASS-2 trial, which compared tirzepatide to semaglutide in type 2 diabetes patients, also showed tirzepatide outperforming at all three doses on both A1c reduction and weight loss (Frias et al., 2021). That trial enrolled 1,879 participants.

A 2023 real-world evidence study using Truveta electronic health records compared 41,223 patients who started either drug and found that tirzepatide-treated patients reached 5%, 10%, and 15% weight loss milestones significantly faster than semaglutide-treated patients (Rodriguez et al., 2023).

None of this means semaglutide doesn't work. It's a strong drug with a long track record. The picture being painted by the data is that tirzepatide produces more weight loss, on average, in most populations. The margin is clinically meaningful.

Real-World Weight Loss: What to Actually Expect

Clinical trial numbers are what happen when people are highly adherent and closely monitored. Real-world numbers are lower.

A 2025 real-world cohort study found that average weight reduction in clinical practice was lower than in the phase 3 trials, with 20-50% of patients discontinuing within the first year, often at lower doses than trials used (Thomsen et al., 2025). When researchers focused on highly adherent patients, outcomes approached trial-level results.

A 2025 real-world effectiveness study comparing patients initiated on semaglutide or tirzepatide found tirzepatide associated with greater weight loss and glycemic improvement at 12 months (Hoog et al., 2025). A short-term cost-effectiveness analysis also found tirzepatide cost-effective compared to semaglutide when looking at quality-adjusted life years (Liu et al., 2025).

A separate 2025 analysis found that weight and glycemic outcomes after stopping treatment were worse for patients who discontinued early — reinforcing that these medications need long-term commitment to maintain results (Gasoyan et al., 2025).

The practical implication: the drug only works while you're taking it, at a dose that actually matches what was studied. Staying on a therapeutic dose matters more than which medication you choose.

Side Effects: Similarities and Key Differences

Both medications cause gastrointestinal side effects: nausea, vomiting, diarrhea, constipation. That's the GLP-1 mechanism slowing gastric emptying. It's not unique to either drug.

The FDA FAERS database contains over 120,921 adverse event reports linked to these medications. The most commonly reported issues: fatigue, nausea, headache, and gastrointestinal symptoms. Only 100 of those reports were classified as serious. Given the tens of millions of people now using these drugs, that's a very low serious adverse event rate.

The good news on the SURMOUNT-5 comparison: the rate of nausea and other GI side effects was actually similar between tirzepatide and semaglutide despite tirzepatide producing more weight loss. Tirzepatide did not produce more GI side effects just because it's more potent.

A Mayo Clinic Proceedings review found that 40-70% of GLP-1 patients experience some GI symptoms, with management strategies including smaller meals, slower dose titration, and avoiding high-fat foods (Saha et al., 2025). Most symptoms improve as the body adjusts over 4-12 weeks.

For patients using these drugs before surgery, the same review flagged that long-acting formulations like semaglutide and tirzepatide are associated with higher rates of retained gastric contents. Your anesthesiologist needs to know you're on one of these before any procedure.

One safety note that gets under-discussed: both drugs carry a black box warning about thyroid C-cell tumors observed in rodent studies. This risk hasn't been confirmed in humans, but both drugs are contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

The Muscle Mass Problem

Both drugs cause some muscle loss along with fat loss. This is one of the most underappreciated issues in GLP-1 therapy, and it matters especially if you're over 40 or already lean.

In typical weight loss, roughly 25-30% of the weight lost is muscle. The concern with GLP-1 drugs is that this ratio may be similar or slightly higher. Ongoing clinical research is tracking body composition changes in patients on both semaglutide and tirzepatide at 3, 6, and 12 months, specifically measuring skeletal muscle mass, grip strength, and gait speed alongside fat loss (NCT07156331).

Animal data points to tirzepatide having a slight advantage in preserving lean mass due to GIP receptor effects on adipose tissue, but this hasn't been confirmed in large human trials. Research with an apelin receptor agonist added to tirzepatide showed body composition improvements in mice, with lean mass rising from 60% to 69% of body weight compared to tirzepatide alone (Wang et al., 2024). Human data is pending.

The practical recommendation from every physician managing patients on these drugs: resistance training and high-protein intake are not optional. They're part of the protocol. If you're taking a GLP-1 medication without lifting and eating 0.7-1g of protein per pound of body weight, you're losing muscle you're going to regret losing. See our guide on working with a Registered Dietitian for Weight Loss for specifics on protein targets.

How They're Dosed

Both are once-weekly subcutaneous injections. Neither is a set-it-and-forget-it dose. Both require titration starting at a low dose to minimize GI side effects.

Semaglutide (Wegovy) dosing schedule:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Tirzepatide (Zepbound) dosing schedule:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly (optional hold)
• Weeks 13-16: 10 mg weekly (optional hold)
• Weeks 17-20: 12.5 mg weekly (optional hold)
• Week 21 onward: 15 mg weekly (maintenance)

The titration isn't just a formality. Many patients tolerate an extended stay at a lower dose before moving up, especially if they're getting good weight loss results at 5 mg or 1 mg respectively. Forcing escalation when the current dose is working adds GI side effects without necessarily adding weight loss.

FDA Approval and Availability

Both are FDA-approved. That's worth saying directly because competitors in the GLP-1 content space often blur this.

Semaglutide:

• Ozempic: FDA-approved for type 2 diabetes (2017)
• Wegovy: FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related condition (2021)
• Rybelsus: FDA-approved oral semaglutide for type 2 diabetes (2019)

Tirzepatide:

• Mounjaro: FDA-approved for type 2 diabetes (2022)
• Zepbound: FDA-approved for chronic weight management, same criteria as Wegovy (2023)

Both drugs are given for weight loss with a BMI of 30+, or BMI 27+ with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea). If you don't meet those criteria on paper, coverage and access become more complicated.

Cost, Insurance, and How to Access

This is where it gets frustrating. These are not cheap drugs.

Semaglutide (Wegovy): List price approximately $1,300-1,400/month without insurance.

Tirzepatide (Zepbound): List price approximately $1,000-1,300/month without insurance.

Insurance coverage is inconsistent and getting worse. Many commercial plans cover Ozempic or Mounjaro for type 2 diabetes but specifically exclude Wegovy and Zepbound for weight management, even though they're the same active ingredient at higher doses. Medicare Part D was prohibited from covering weight loss drugs until very recently and coverage is still limited.

Manufacturer savings programs exist. Novo Nordisk's savings card for Wegovy can bring the cost down to $0/month for eligible commercially-insured patients. Eli Lilly's Zepbound savings card offers similar programs. These only apply if you have qualifying commercial insurance, not Medicare or Medicaid.

For patients paying out of pocket, compounded semaglutide and tirzepatide have been widely available during shortage periods, though the FDA has been tightening access to compounded versions as branded supplies normalize.

HEXIS providers work with you on access. We start by reviewing your insurance situation, walk through the savings programs, and discuss the right path forward based on your labs and goals. Schedule a consultation with semaglutide vs tirzepatide guidance included.

Switching from One to the Other

Patients switch between these medications more often than you'd think. Sometimes due to side effects, sometimes insurance changes, sometimes because they plateaued on one and want to try the other.

Switching is generally straightforward. Most physicians will start you at a lower dose of the new medication rather than converting directly to an equivalent dose, because your tolerance from one drug doesn't fully transfer to the other.

If you're switching from semaglutide to tirzepatide because you're not seeing enough weight loss, expect 4-6 weeks before you'll know if the change is working. Tirzepatide's additional GIP activation takes time to produce its additional effects.

More on managing side effects and transition guidance at our article on Ozempic side effects and what to do about them.

Ozempic Face and Body Composition Changes

One more thing that doesn't get enough clinical attention: GLP-1-associated facial volume loss. Patients lose fat everywhere, including in the face, and rapid weight loss can make people look gaunt or aged despite feeling better metabolically.

This is more noticeable with faster or larger weight losses, and more common in patients who were already lean in the face before starting. It's not dangerous. It's also not avoidable through medication choice — both semaglutide and tirzepatide can cause it. Slower, more gradual loss mitigates it somewhat.

We cover this in detail at Ozempic Face: What It Is and How to Manage It.

FAQ

Is tirzepatide stronger than semaglutide?

Yes, based on available trial data. In the SURMOUNT-5 head-to-head trial, tirzepatide produced approximately 47% more weight loss than semaglutide at 72 weeks. The dual GLP-1 and GIP receptor mechanism appears to produce greater appetite suppression and metabolic effects than GLP-1 activation alone. Individual responses vary, and some patients do equally well or better on semaglutide.

Which causes less nausea: semaglutide or tirzepatide?

Nausea rates were similar between the two drugs in head-to-head comparisons, including SURMOUNT-5. Despite tirzepatide producing more weight loss, it doesn't appear to cause significantly more GI side effects. How nausea affects you is more about how fast you titrate, what you eat, and your individual GI sensitivity than which drug you're on.

Can I switch from Ozempic to Mounjaro?

Yes. This is a common transition that physicians make regularly. You'll typically restart at a lower tirzepatide dose rather than converting one-to-one. Give it 6-8 weeks at the new medication before evaluating whether the change is producing better results. The reason most patients switch is either insurance coverage, GI side effects, or wanting better weight loss.

Does insurance cover Wegovy or Zepbound?

Coverage is inconsistent and changes frequently. Many commercial plans cover Ozempic (semaglutide for diabetes) but exclude Wegovy (semaglutide for weight loss) even though it's the same drug. Manufacturer savings cards can bring costs down significantly for commercially insured patients who don't qualify for coverage. Medicare coverage of weight loss drugs is still limited. Your HEXIS provider will review your specific insurance before prescribing.

How do I decide between semaglutide and tirzepatide?

The evidence points to tirzepatide producing more weight loss, on average (about 47% more in the only direct head-to-head trial). But that's a population average. Your decision should also factor in your insurance coverage, your GI history, whether you have type 2 diabetes, and your cost tolerance. A physician who's reviewed your full labs and history is the only one who can weigh those factors for you specifically. At HEXIS, that's how every protocol starts.

The HEXIS Approach to GLP-1 Therapy

The medication choice is one decision. But it's downstream of other decisions that matter more: whether your thyroid, cortisol, and insulin function are actually working against your weight loss. Whether you're losing muscle mass without realizing it. Whether you have the protein and resistance training in place to preserve your lean mass.

Your HEXIS provider looks at the full picture before recommending which GLP-1 fits your situation. If you want to explore whether semaglutide vs tirzepatide is the right question for you, we start with labs, not a one-size-fits-all prescription. Book a consultation here and we'll review what your numbers actually show.

For a broader comparison of all current GLP-1 medications, see GLP-1 Medications Compared: The Full Breakdown.

---